STAT Plus: Tyme Technologies misleads with new data on pancreatic cancer drug
NIH
Tyme Technologies says new data show its pancreatic cancer drug “improves survival." But there are red flags, and the data fall below investor expectations.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario